Project company Xsight Optics successfully participates in start-up competition – prize money finances relevant R&D project
Xsight Optics, based in Jena (Germany), a project company of Xlife Sciences AG (SIX: XLS), has successfully participated in this year's StartUp competition get started 2gether organized by the Thuringia Research and Technology Association and the Thuringia Ministry of Economics: The company won funding for a relevant new research and development project, and was also awarded the audience prize.
|
Xlife Sciences AG / Key word(s): Miscellaneous Project company Xsight Optics successfully participates in start-up competition – prize money finances relevant R&D project 16.05.2022 / 07:05 Xsight Optics, based in Jena (Germany), a project company of Xlife Sciences AG (SIX: XLS), has successfully participated in this year's StartUp competition “get started 2gether” organized by the Thuringia Research and Technology Association and the Thuringia Ministry of Economics: The company won funding for a relevant new research and development project, and was also awarded the audience prize. Xsight Optics' vision is to expand human-centered, digital care. To this end, the company is developing a portable optical sensor with which medical staff in hospitals and care facilities can, for example, record the heart rate, oxygen saturation, temperature, and respiratory rate of patients from a safe distance without contact (and transfer them directly to an already existing Documentation system). This mobile sensor derives these health parameters from several image properties through a clever combination of optical technology, microelectronics, and AI-supported algorithms. Central to this is secure and reliable imaging software. The awarded prize money of EUR 80,000 will enable Xsight Optis to finance a corresponding R&D project with the Intelligent Systems Department of the Institute for Applied Building Research Weimar. Oliver R. Baumann, CEO of Xlife Sciences, comments: “We warmly congratulate CEO Maria Nisser and CSO Jan Sperrhake of our project company Xsight Optics for their doubly successful pitch at the renowned Thuringian StartUp funding award “get started 2gether”. The funding thus achieved for the interdisciplinary research and development project with the experts in computer vision and data analysis from the Institute for Applied Building Research Weimar is a relevant milestone for Xsight Optics' endeavor to expand human-centered, digital care.”
Financial calendar Ordinary General Assembly 2022 June 20, 2022 2022 Half-Year Results September 28, 2022
Contact Information for journalists: IRF Reputation AG, Valentin Handschin, [email protected] Information for investors: Xlife Sciences AG, Dennis Lennartz, [email protected] Xlife Sciences AG
Talacker 35
8001 Zürich
Telefon: 0041 44 385 84 60
E-Mail: [email protected]
Internet: www.xlifesciences.ch
ISIN: CH0461929603
WKN: A2PK6Z
Börsen: SIX Swiss Exchange
About Xlife Sciences AG (SIX: XLS) Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch Disclaimer Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.
End of Media Release |
| Language: | English |
| Company: | Xlife Sciences AG |
| Talacker 35 | |
| 8001 Zürich | |
| Switzerland | |
| Phone: | +41 44 385 84 60 |
| E-mail: | [email protected] |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| Valor: | A2PK6Z |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1352665 |
| End of News | EQS News Service |
|
|
1352665 16.05.2022